• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Tango Therapeutics, Inc. - Common Stock (NQ:TNGX)

    27.46 -0.31 (-1.12%)
    Streaming Delayed Price Updated: 11:19 AM EDT, Apr 22, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Tango Therapeutics, Inc. - Common Stock

    News headline image
    Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
    From Tango Therapeutics Sub, Inc
    Via GlobeNewswire
    News headline image
    The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
    Issued on behalf of Oncolytics Biotech Inc. 
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Tango Therapeutics, Inc.
    Via Business Wire
    News headline image
    Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
    From Tango Therapeutics, Inc.
    Via Business Wire
    News headline image
    Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
    From Tango Therapeutics, Inc.
    Via Business Wire
    News headline image
    Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program
    From Tango Therapeutics, Inc.
    Via Business Wire
    News headline image
    Tango Therapeutics to Participate in Upcoming Investor Conferences
    From Tango Therapeutics, Inc.
    Via Business Wire
    News headline image
    Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
    From Tango Therapeutics, Inc.
    Via Business Wire
    News headline image
    Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
    From Tango Therapeutics, Inc.
    Via Business Wire
    News headline image
    Tango Therapeutics Announces Discontinuation of TNG348 Program
    From Tango Therapeutics
    Via Business Wire
    News headline image
    Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
    From Tango Therapeutics, Inc.
    Via Business Wire
    News headline image
    Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Tango Therapeutics, Inc.
    Via Business Wire
    News headline image
    Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
    From Tango Therapeutics, Inc.
    Via Business Wire
    News headline image
    Tango Therapeutics to Participate in Upcoming Investor Conferences
    From Tango Therapeutics, Inc.
    Via Business Wire
    Pancreatic Cancer Treatments Poised for Major Advances in 2024
    EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INCY),(NASDAQ:TNGX),(NASDAQ:RYZB),(NYSE:BMY) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    Special Purpose Acquisition Companies: The Briscoe Law Firm, PLLC Announce Investigation into the following SPACs
    From The Briscoe Law Firm, PLLC
    Via Business Wire
    News headline image
    Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Tango Therapeutics, Inc (TNGX) Investigation
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    News headline image
    HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    News headline image
    Tango Therapeutics Announces Presentation of Preclinical Data on Lead Program and Discovery Platform in Five Abstracts Accepted at AACR-NCI-EORTC 2021
    From Tango Therapeutics, Inc.
    Via Business Wire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.